Table 1.
Clinical characteristics of 105 NPC patients according to YTHDC2 expression levels.
YTHDC2 | |||||
---|---|---|---|---|---|
Feature | Low | High | n | χ2 | P |
All cases | 64 | 41 | 105 | ||
Gender | |||||
Male | 44 | 21 | 65 | 3.257 | 0.099 |
Female | 20 | 20 | 40 | ||
Age (years) | |||||
≤50 | 38 | 31 | 69 | 2.923 | 0.097 |
>50 | 26 | 10 | 36 | ||
TMN | |||||
Stage I + Stage II | 40 | 21 | 61 | 1.306 | 0.312 |
Stage III + Stage IV | 24 | 20 | 44 | ||
Tumor size (mm) | |||||
≤30 | 33 | 17 | 50 | 1.022 | 0.326 |
>30 | 31 | 24 | 55 | ||
Radiotherapy effect | |||||
Complete response | 37 | 15 | 52 | 4.505 | 0.034* |
Partial response | 27 | 26 | 53 | ||
Pathological type | |||||
Undifferentiated non-keratinizing carcinoma | 29 | 18 | 47 | 0.02 | 0.887 |
Differentiated non-keratinizing carcinoma | 35 | 23 | 58 |
χ2 test was used to test the association between two categorical variables.
Statistically significant.